Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia / A via receptor NMDA-óxido nítrico-GMP cíclico como alvo para o desenvolvimento de medicações antipsicóticas não-dopaminérgicas para a esquizofrenia
Braz. J. Psychiatry (São Paulo, 1999, Impr.)
;
33(3): 223-224, Sept. 2011. tab
Article
in English
| LILACS
| ID: lil-609076
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Schizophrenia
/
Antipsychotic Agents
/
Receptors, N-Methyl-D-Aspartate
/
Cyclic GMP
/
Nitric Oxide
Type of study:
Etiology study
Limits:
Humans
Language:
English
Journal:
Braz. J. Psychiatry (São Paulo, 1999, Impr.)
Journal subject:
Psychiatry
Year:
2011
Type:
Article
Affiliation country:
Brazil
/
Canada
Institution/Affiliation country:
Universidade Federal do Rio Grande do Norte/BR
/
Universidade de São Paulo/BR
/
University of Alberta/CA
Similar
MEDLINE
...
LILACS
LIS